euctr_id,title,reg_date,other_id,field,provenance
2020-002510-40,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.",2020-10-08,NA,US NCT number,protocol
2020-002510-40,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.",2020-10-08,NA,other,protocol
2020-002510-40,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.",2020-10-08,NA,US NCT number,results
2020-002510-40,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.",2020-10-08,NA,ISRCTN number,results
2020-002282-33,Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT),2020-05-29,NA,US NCT number,protocol
2020-002282-33,Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT),2020-05-29,NA,other,protocol
2020-002282-33,Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT),2020-05-29,NA,US NCT number,results
2020-002282-33,Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT),2020-05-29,NA,ISRCTN number,results
2017-004458-41,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with chronic spontaneous urticaria despite H1-antihistamine treatment.",2018-07-09,NA,US NCT number,protocol
2017-004458-41,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with chronic spontaneous urticaria despite H1-antihistamine treatment.",2018-07-09,NA,other,protocol
2017-004458-41,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with chronic spontaneous urticaria despite H1-antihistamine treatment.",2018-07-09,NA,US NCT number,results
2017-004458-41,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with chronic spontaneous urticaria despite H1-antihistamine treatment.",2018-07-09,NA,ISRCTN number,results
2017-001604-30,"Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial",2017-09-29,NA,US NCT number,protocol
2017-001604-30,"Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial",2017-09-29,NA,other,protocol
2017-001604-30,"Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial",2017-09-29,NCT03444103,US NCT number,results
2017-001604-30,"Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial",2017-09-29,NA,ISRCTN number,results
2016-004825-17,A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy,2017-11-09,NA,US NCT number,protocol
2016-004825-17,A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy,2017-11-09,NA,other,protocol
2016-004825-17,A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy,2017-11-09,NA,US NCT number,results
2016-004825-17,A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy,2017-11-09,NA,ISRCTN number,results
2016-003828-23,A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS) ,2017-01-31,NA,US NCT number,protocol
2016-003828-23,A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS) ,2017-01-31,NA,other,protocol
2016-003828-23,A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS) ,2017-01-31,NCT03046381,US NCT number,results
2016-003828-23,A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS) ,2017-01-31,NA,ISRCTN number,results
2016-002370-12,PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME,2016-07-21,NA,US NCT number,protocol
2016-002370-12,PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME,2016-07-21,NA,other,protocol
2016-002370-12,PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME,2016-07-21,NA,US NCT number,results
2016-002370-12,PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME,2016-07-21,NA,ISRCTN number,results
2016-001777-33,EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR,2016-06-06,NA,US NCT number,protocol
2016-001777-33,EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR,2016-06-06,NA,other,protocol
2016-001777-33,EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR,2016-06-06,NCT02758964,US NCT number,results
2016-001777-33,EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR,2016-06-06,NA,ISRCTN number,results
2016-000615-33,Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL),2016-07-06,NCT02758782,US NCT number,protocol
2016-000615-33,Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL),2016-07-06,NA,other,protocol
2016-000615-33,Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL),2016-07-06,NCT02758782,US NCT number,results
2016-000615-33,Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL),2016-07-06,NA,ISRCTN number,results
2015-005346-58,Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI),2016-08-05,NA,US NCT number,protocol
2015-005346-58,Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI),2016-08-05,NA,other,protocol
2015-005346-58,Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI),2016-08-05,NCT04114188,US NCT number,results
2015-005346-58,Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI),2016-08-05,NA,ISRCTN number,results
2015-001456-29,"A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD)",2015-07-08,NA,US NCT number,protocol
2015-001456-29,"A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD)",2015-07-08,NA,other,protocol
2015-001456-29,"A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD)",2015-07-08,NA,US NCT number,results
2015-001456-29,"A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD)",2015-07-08,NA,ISRCTN number,results
2015-000538-31,NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint,2015-04-07,NA,US NCT number,protocol
2015-000538-31,NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint,2015-04-07,NA,other,protocol
2015-000538-31,NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint,2015-04-07,NA,US NCT number,results
2015-000538-31,NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint,2015-04-07,NA,ISRCTN number,results
2015-000465-31,"Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression",2016-03-30,NA,US NCT number,protocol
2015-000465-31,"Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression",2016-03-30,NA,other,protocol
2015-000465-31,"Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression",2016-03-30,NA,US NCT number,results
2015-000465-31,"Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression",2016-03-30,NA,ISRCTN number,results
2014-005344-17,"Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study.",2015-01-02,NA,US NCT number,protocol
2014-005344-17,"Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study.",2015-01-02,NA,other,protocol
2014-005344-17,"Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study.",2015-01-02,NA,US NCT number,results
2014-005344-17,"Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study.",2015-01-02,NA,ISRCTN number,results
2014-005239-15,Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?,2016-02-03,NA,US NCT number,protocol
2014-005239-15,Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?,2016-02-03,NA,other,protocol
2014-005239-15,Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?,2016-02-03,NCT03062150,US NCT number,results
2014-005239-15,Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?,2016-02-03,NA,ISRCTN number,results
2014-004551-32,Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety,2015-08-28,NA,US NCT number,protocol
2014-004551-32,Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety,2015-08-28,NA,other,protocol
2014-004551-32,Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety,2015-08-28,NA,US NCT number,results
2014-004551-32,Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety,2015-08-28,NA,ISRCTN number,results
2014-002392-28,Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity,2014-08-04,NA,US NCT number,protocol
2014-002392-28,Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity,2014-08-04,NA,other,protocol
2014-002392-28,Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity,2014-08-04,NCT02507492,US NCT number,results
2014-002392-28,Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity,2014-08-04,NA,ISRCTN number,results
2014-001551-22,Reduction of postoperative wound infections by antiseptica,2014-06-18,NA,US NCT number,protocol
2014-001551-22,Reduction of postoperative wound infections by antiseptica,2014-06-18,NA,other,protocol
2014-001551-22,Reduction of postoperative wound infections by antiseptica,2014-06-18,NA,US NCT number,results
2014-001551-22,Reduction of postoperative wound infections by antiseptica,2014-06-18,NA,ISRCTN number,results
2014-000181-21,"Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.",2014-04-23,NA,US NCT number,protocol
2014-000181-21,"Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.",2014-04-23,NA,other,protocol
2014-000181-21,"Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.",2014-04-23,NA,US NCT number,results
2014-000181-21,"Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.",2014-04-23,NA,ISRCTN number,results
2013-005362-19,Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB),2013-12-18,NA,US NCT number,protocol
2013-005362-19,Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB),2013-12-18,NA,other,protocol
2013-005362-19,Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB),2013-12-18,NA,US NCT number,results
2013-005362-19,Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB),2013-12-18,NA,ISRCTN number,results
2013-004130-15,"Investigator-initiated clinical research trial on the effects of 5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia",2014-03-05,NA,US NCT number,protocol
2013-004130-15,"Investigator-initiated clinical research trial on the effects of 5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia",2014-03-05,NA,other,protocol
2013-004130-15,"Investigator-initiated clinical research trial on the effects of 5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia",2014-03-05,NA,US NCT number,results
2013-004130-15,"Investigator-initiated clinical research trial on the effects of 5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia",2014-03-05,NA,ISRCTN number,results
2013-003601-25,"A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Heart Failure and diabetes mellitus type II",2013-11-12,NA,US NCT number,protocol
2013-003601-25,"A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Heart Failure and diabetes mellitus type II",2013-11-12,NA,other,protocol
2013-003601-25,"A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Heart Failure and diabetes mellitus type II",2013-11-12,NA,US NCT number,results
2013-003601-25,"A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Heart Failure and diabetes mellitus type II",2013-11-12,NA,ISRCTN number,results
2013-002409-75,"Intra-individual, comparison of the MRI contrast agents gadoxetic acid (Primovist®) versus gadoterate meglumine (Dotarem®) in liver MRI of patients with HCC and underlying cirrhosis",2013-08-23,NA,US NCT number,protocol
2013-002409-75,"Intra-individual, comparison of the MRI contrast agents gadoxetic acid (Primovist®) versus gadoterate meglumine (Dotarem®) in liver MRI of patients with HCC and underlying cirrhosis",2013-08-23,NA,other,protocol
2013-002409-75,"Intra-individual, comparison of the MRI contrast agents gadoxetic acid (Primovist®) versus gadoterate meglumine (Dotarem®) in liver MRI of patients with HCC and underlying cirrhosis",2013-08-23,NA,US NCT number,results
2013-002409-75,"Intra-individual, comparison of the MRI contrast agents gadoxetic acid (Primovist®) versus gadoterate meglumine (Dotarem®) in liver MRI of patients with HCC and underlying cirrhosis",2013-08-23,NA,ISRCTN number,results
2013-000823-15,Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery,2013-11-19,NA,US NCT number,protocol
2013-000823-15,Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery,2013-11-19,NA,other,protocol
2013-000823-15,Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery,2013-11-19,NCT02096068,US NCT number,results
2013-000823-15,Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery,2013-11-19,NA,ISRCTN number,results
2013-000416-24,THE EFFECT OF AZELAIC ACID ON SYMPTOMS OF ACNE IN FEMALE PATIENTS AGE 20-45 WITH MILD TO MODERATE PAPULOPUSTULAR ACNE (ACNE TARDA),2013-04-08,NA,US NCT number,protocol
2013-000416-24,THE EFFECT OF AZELAIC ACID ON SYMPTOMS OF ACNE IN FEMALE PATIENTS AGE 20-45 WITH MILD TO MODERATE PAPULOPUSTULAR ACNE (ACNE TARDA),2013-04-08,NA,other,protocol
2013-000416-24,THE EFFECT OF AZELAIC ACID ON SYMPTOMS OF ACNE IN FEMALE PATIENTS AGE 20-45 WITH MILD TO MODERATE PAPULOPUSTULAR ACNE (ACNE TARDA),2013-04-08,NA,US NCT number,results
2013-000416-24,THE EFFECT OF AZELAIC ACID ON SYMPTOMS OF ACNE IN FEMALE PATIENTS AGE 20-45 WITH MILD TO MODERATE PAPULOPUSTULAR ACNE (ACNE TARDA),2013-04-08,NA,ISRCTN number,results
2012-005726-30,"A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)",2013-05-29,NA,US NCT number,protocol
2012-005726-30,"A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)",2013-05-29,NA,other,protocol
2012-005726-30,"A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)",2013-05-29,NA,US NCT number,results
2012-005726-30,"A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)",2013-05-29,NA,ISRCTN number,results
2012-005652-42,Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients,2013-06-12,NA,US NCT number,protocol
2012-005652-42,Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients,2013-06-12,NA,other,protocol
2012-005652-42,Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients,2013-06-12,NA,US NCT number,results
2012-005652-42,Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients,2013-06-12,NA,ISRCTN number,results
2012-004111-32,"Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application of MAL-PDT versus lesion adapted cryotherapy",2012-11-09,NA,US NCT number,protocol
2012-004111-32,"Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application of MAL-PDT versus lesion adapted cryotherapy",2012-11-09,NA,other,protocol
2012-004111-32,"Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application of MAL-PDT versus lesion adapted cryotherapy",2012-11-09,NA,US NCT number,results
2012-004111-32,"Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application of MAL-PDT versus lesion adapted cryotherapy",2012-11-09,NA,ISRCTN number,results
2012-003943-32,Influence of diabetes control on treatment of diabetic macular edema with ranibizumab,2015-03-31,NA,US NCT number,protocol
2012-003943-32,Influence of diabetes control on treatment of diabetic macular edema with ranibizumab,2015-03-31,NA,other,protocol
2012-003943-32,Influence of diabetes control on treatment of diabetic macular edema with ranibizumab,2015-03-31,NA,US NCT number,results
2012-003943-32,Influence of diabetes control on treatment of diabetic macular edema with ranibizumab,2015-03-31,NA,ISRCTN number,results
2012-003882-17,"Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study.",2013-04-08,NA,US NCT number,protocol
2012-003882-17,"Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study.",2013-04-08,NA,other,protocol
2012-003882-17,"Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study.",2013-04-08,NCT02071615,US NCT number,results
2012-003882-17,"Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study.",2013-04-08,NA,ISRCTN number,results
2012-003621-21,"Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with ventilator-associated pneumonia (VAP)",2013-06-06,NA,US NCT number,protocol
2012-003621-21,"Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with ventilator-associated pneumonia (VAP)",2013-06-06,NA,other,protocol
2012-003621-21,"Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with ventilator-associated pneumonia (VAP)",2013-06-06,NA,US NCT number,results
2012-003621-21,"Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with ventilator-associated pneumonia (VAP)",2013-06-06,NA,ISRCTN number,results
2012-003217-33,"Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)",2012-08-13,NA,US NCT number,protocol
2012-003217-33,"Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)",2012-08-13,NA,other,protocol
2012-003217-33,"Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)",2012-08-13,NA,US NCT number,results
2012-003217-33,"Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)",2012-08-13,NA,ISRCTN number,results
2012-000443-27,Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem,2012-03-19,NA,US NCT number,protocol
2012-000443-27,Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem,2012-03-19,NA,other,protocol
2012-000443-27,Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem,2012-03-19,NA,US NCT number,results
2012-000443-27,Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem,2012-03-19,NA,ISRCTN number,results
2012-000411-91,"Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial",2012-12-04,NA,US NCT number,protocol
2012-000411-91,"Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial",2012-12-04,NA,other,protocol
2012-000411-91,"Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial",2012-12-04,NA,US NCT number,results
2012-000411-91,"Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial",2012-12-04,NA,ISRCTN number,results
2012-000188-25,Lormetazepam versus Midazolam used as sedatives for critically ill patients.,2013-03-14,NCT02022592,US NCT number,protocol
2012-000188-25,Lormetazepam versus Midazolam used as sedatives for critically ill patients.,2013-03-14,NA,other,protocol
2012-000188-25,Lormetazepam versus Midazolam used as sedatives for critically ill patients.,2013-03-14,NCT02022592,US NCT number,results
2012-000188-25,Lormetazepam versus Midazolam used as sedatives for critically ill patients.,2013-03-14,NA,ISRCTN number,results
2011-005615-87,"A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with urticaria factitia refractory to standard treatment",2012-07-24,NA,US NCT number,protocol
2011-005615-87,"A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with urticaria factitia refractory to standard treatment",2012-07-24,NA,other,protocol
2011-005615-87,"A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with urticaria factitia refractory to standard treatment",2012-07-24,NA,US NCT number,results
2011-005615-87,"A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with urticaria factitia refractory to standard treatment",2012-07-24,NA,ISRCTN number,results
2011-004944-23,,2011-12-05,NA,US NCT number,protocol
2011-004944-23,,2011-12-05,NA,other,protocol
2011-004944-23,,2011-12-05,NA,US NCT number,results
2011-004944-23,,2011-12-05,NA,ISRCTN number,results
2011-004787-30,Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,2012-07-13,NA,US NCT number,protocol
2011-004787-30,Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,2012-07-13,NA,other,protocol
2011-004787-30,Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,2012-07-13,NA,US NCT number,results
2011-004787-30,Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,2012-07-13,NA,ISRCTN number,results
2011-004585-15,"Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes",2012-09-06,NA,US NCT number,protocol
2011-004585-15,"Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes",2012-09-06,NA,other,protocol
2011-004585-15,"Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes",2012-09-06,NA,US NCT number,results
2011-004585-15,"Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes",2012-09-06,NA,ISRCTN number,results
2011-004463-69,Investigation of Radiation Retinopathy (RadiRet Study),2012-08-03,NA,US NCT number,protocol
2011-004463-69,Investigation of Radiation Retinopathy (RadiRet Study),2012-08-03,DRKS 00003246,other,protocol
2011-004463-69,Investigation of Radiation Retinopathy (RadiRet Study),2012-08-03,NA,US NCT number,results
2011-004463-69,Investigation of Radiation Retinopathy (RadiRet Study),2012-08-03,NA,ISRCTN number,results
2011-004393-28,"""Effectiveness of leech therapy in treatment of chronic low back pain - a randomised controlled clinical study""",2011-12-09,NA,US NCT number,protocol
2011-004393-28,"""Effectiveness of leech therapy in treatment of chronic low back pain - a randomised controlled clinical study""",2011-12-09,NA,other,protocol
2011-004393-28,"""Effectiveness of leech therapy in treatment of chronic low back pain - a randomised controlled clinical study""",2011-12-09,NA,US NCT number,results
2011-004393-28,"""Effectiveness of leech therapy in treatment of chronic low back pain - a randomised controlled clinical study""",2011-12-09,NA,ISRCTN number,results
2011-004094-93,"Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)",2012-01-27,NA,US NCT number,protocol
2011-004094-93,"Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)",2012-01-27,NA,other,protocol
2011-004094-93,"Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)",2012-01-27,NA,US NCT number,results
2011-004094-93,"Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)",2012-01-27,NA,ISRCTN number,results
2011-003746-41,"A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU)",2011-11-28,NA,US NCT number,protocol
2011-003746-41,"A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU)",2011-11-28,NA,other,protocol
2011-003746-41,"A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU)",2011-11-28,NA,US NCT number,results
2011-003746-41,"A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU)",2011-11-28,NA,ISRCTN number,results
2011-002785-20,Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis,2011-08-11,NA,US NCT number,protocol
2011-002785-20,Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis,2011-08-11,NA,other,protocol
2011-002785-20,Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis,2011-08-11,NA,US NCT number,results
2011-002785-20,Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis,2011-08-11,NA,ISRCTN number,results
2011-001689-16,"Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA TREAT)",2013-02-04,NA,US NCT number,protocol
2011-001689-16,"Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA TREAT)",2013-02-04,German Register of Clinical Trials DRKS00000796,other,protocol
2011-001689-16,"Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA TREAT)",2013-02-04,NA,US NCT number,results
2011-001689-16,"Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA TREAT)",2013-02-04,ISRCTN46445413,ISRCTN number,results
2011-001474-25,"A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma",2011-09-20,NA,US NCT number,protocol
2011-001474-25,"A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma",2011-09-20,NA,other,protocol
2011-001474-25,"A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma",2011-09-20,NA,US NCT number,results
2011-001474-25,"A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma",2011-09-20,NA,ISRCTN number,results
2011-001403-12,Carbon Dioxide for the Treatment of Febrile Seizures,2011-10-28,NA,US NCT number,protocol
2011-001403-12,Carbon Dioxide for the Treatment of Febrile Seizures,2011-10-28,NA,other,protocol
2011-001403-12,Carbon Dioxide for the Treatment of Febrile Seizures,2011-10-28,NCT01370044,US NCT number,results
2011-001403-12,Carbon Dioxide for the Treatment of Febrile Seizures,2011-10-28,NA,ISRCTN number,results
2011-001398-19,D-cycloserine augmented exposure therapy in patients with agoraphobia,2011-05-30,NA,US NCT number,protocol
2011-001398-19,D-cycloserine augmented exposure therapy in patients with agoraphobia,2011-05-30,NA,other,protocol
2011-001398-19,D-cycloserine augmented exposure therapy in patients with agoraphobia,2011-05-30,NCT01928823,US NCT number,results
2011-001398-19,D-cycloserine augmented exposure therapy in patients with agoraphobia,2011-05-30,NA,ISRCTN number,results
2011-001232-27,Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH,2011-12-27,NA,US NCT number,protocol
2011-001232-27,Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH,2011-12-27,NA,other,protocol
2011-001232-27,Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH,2011-12-27,NA,US NCT number,results
2011-001232-27,Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH,2011-12-27,NA,ISRCTN number,results
2011-001027-20,"A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.",2011-12-05,NA,US NCT number,protocol
2011-001027-20,"A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.",2011-12-05,NA,other,protocol
2011-001027-20,"A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.",2011-12-05,NCT02204293,US NCT number,results
2011-001027-20,"A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.",2011-12-05,NA,ISRCTN number,results
2011-000844-56,"UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study",2011-06-09,NCT01330901,US NCT number,protocol
2011-000844-56,"UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study",2011-06-09,NA,other,protocol
2011-000844-56,"UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study",2011-06-09,NA,US NCT number,results
2011-000844-56,"UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study",2011-06-09,NA,ISRCTN number,results
2010-024379-15,"Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study. - The PaFLO study.",2011-07-20,NA,US NCT number,protocol
2010-024379-15,"Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study. - The PaFLO study.",2011-07-20,NA,other,protocol
2010-024379-15,"Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study. - The PaFLO study.",2011-07-20,NCT01503372,US NCT number,results
2010-024379-15,"Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study. - The PaFLO study.",2011-07-20,NA,ISRCTN number,results
2010-024156-28,"A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome",2011-04-07,NA,US NCT number,protocol
2010-024156-28,"A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome",2011-04-07,NA,other,protocol
2010-024156-28,"A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome",2011-04-07,NA,US NCT number,results
2010-024156-28,"A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome",2011-04-07,NA,ISRCTN number,results
2010-023941-31,Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington,2011-03-17,NA,US NCT number,protocol
2010-023941-31,Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington,2011-03-17,NA,other,protocol
2010-023941-31,Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington,2011-03-17,NCT01357681,US NCT number,results
2010-023941-31,Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington,2011-03-17,NA,ISRCTN number,results
2010-023044-32,Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder,2011-03-21,NA,US NCT number,protocol
2010-023044-32,Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder,2011-03-21,NA,other,protocol
2010-023044-32,Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder,2011-03-21,NA,US NCT number,results
2010-023044-32,Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder,2011-03-21,NA,ISRCTN number,results
2010-021861-62,Baclofen for the Treatment of Alcohol Dependence,2010-09-16,NA,US NCT number,protocol
2010-021861-62,Baclofen for the Treatment of Alcohol Dependence,2010-09-16,NA,other,protocol
2010-021861-62,Baclofen for the Treatment of Alcohol Dependence,2010-09-16,NCT01266655,US NCT number,results
2010-021861-62,Baclofen for the Treatment of Alcohol Dependence,2010-09-16,NA,ISRCTN number,results
2010-021775-80,Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma,2010-09-14,NA,US NCT number,protocol
2010-021775-80,Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma,2010-09-14,NA,other,protocol
2010-021775-80,Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma,2010-09-14,NCT01466465,US NCT number,results
2010-021775-80,Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma,2010-09-14,NA,ISRCTN number,results
2010-021604-16,"A double-blind, randomized, placebo controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgery",2010-10-13,NA,US NCT number,protocol
2010-021604-16,"A double-blind, randomized, placebo controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgery",2010-10-13,NA,other,protocol
2010-021604-16,"A double-blind, randomized, placebo controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgery",2010-10-13,NA,US NCT number,results
2010-021604-16,"A double-blind, randomized, placebo controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgery",2010-10-13,NA,ISRCTN number,results
2010-021275-92,"Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated mycophenolate sodium) in combination with a proton pump inhibitor without co-medication.",2010-10-01,NA,US NCT number,protocol
2010-021275-92,"Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated mycophenolate sodium) in combination with a proton pump inhibitor without co-medication.",2010-10-01,NA,other,protocol
2010-021275-92,"Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated mycophenolate sodium) in combination with a proton pump inhibitor without co-medication.",2010-10-01,NA,US NCT number,results
2010-021275-92,"Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated mycophenolate sodium) in combination with a proton pump inhibitor without co-medication.",2010-10-01,NA,ISRCTN number,results
2010-021001-21,"An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms",2010-06-16,NA,US NCT number,protocol
2010-021001-21,"An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms",2010-06-16,NA,other,protocol
2010-021001-21,"An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms",2010-06-16,NA,US NCT number,results
2010-021001-21,"An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms",2010-06-16,NA,ISRCTN number,results
2010-020480-21,Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer,2010-07-28,NA,US NCT number,protocol
2010-020480-21,Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer,2010-07-28,NA,other,protocol
2010-020480-21,Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer,2010-07-28,NA,US NCT number,results
2010-020480-21,Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer,2010-07-28,NA,ISRCTN number,results
2010-020433-13,"Eine 8-wöchige, monozentrische, baseline-kontrollierte offene Studie zur Evaluierung des Einflusses einer “Single pill combination” auf die Blutdrucksenkung bei Patienten mit nicht-kontrolliertem Blutdruck unter freier Therapie",2010-11-26,NA,US NCT number,protocol
2010-020433-13,"Eine 8-wöchige, monozentrische, baseline-kontrollierte offene Studie zur Evaluierung des Einflusses einer “Single pill combination” auf die Blutdrucksenkung bei Patienten mit nicht-kontrolliertem Blutdruck unter freier Therapie",2010-11-26,NA,other,protocol
2010-020433-13,"Eine 8-wöchige, monozentrische, baseline-kontrollierte offene Studie zur Evaluierung des Einflusses einer “Single pill combination” auf die Blutdrucksenkung bei Patienten mit nicht-kontrolliertem Blutdruck unter freier Therapie",2010-11-26,NA,US NCT number,results
2010-020433-13,"Eine 8-wöchige, monozentrische, baseline-kontrollierte offene Studie zur Evaluierung des Einflusses einer “Single pill combination” auf die Blutdrucksenkung bei Patienten mit nicht-kontrolliertem Blutdruck unter freier Therapie",2010-11-26,NA,ISRCTN number,results
2010-020063-21,"“A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",2010-05-21,NA,US NCT number,protocol
2010-020063-21,"“A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",2010-05-21,NA,other,protocol
2010-020063-21,"“A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",2010-05-21,NA,US NCT number,results
2010-020063-21,"“A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",2010-05-21,NA,ISRCTN number,results
2010-019347-18,"Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",2010-04-20,NA,US NCT number,protocol
2010-019347-18,"Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",2010-04-20,NA,other,protocol
2010-019347-18,"Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",2010-04-20,NA,US NCT number,results
2010-019347-18,"Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",2010-04-20,NA,ISRCTN number,results
2010-019344-39,"Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU) Compound: Bilastine",2010-04-15,NA,US NCT number,protocol
2010-019344-39,"Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU) Compound: Bilastine",2010-04-15,NA,other,protocol
2010-019344-39,"Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU) Compound: Bilastine",2010-04-15,NA,US NCT number,results
2010-019344-39,"Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU) Compound: Bilastine",2010-04-15,NA,ISRCTN number,results
2010-019218-26,Offene Verträglichkeitsstudie zur Evaluierung einer subkutanen Injektionslösung von 100 mg Anakinra in Kombination mit Riluzol bei Patienten mit Amyotropher Lateralsklerose (ALS).,2010-12-22,NA,US NCT number,protocol
2010-019218-26,Offene Verträglichkeitsstudie zur Evaluierung einer subkutanen Injektionslösung von 100 mg Anakinra in Kombination mit Riluzol bei Patienten mit Amyotropher Lateralsklerose (ALS).,2010-12-22,NA,other,protocol
2010-019218-26,Offene Verträglichkeitsstudie zur Evaluierung einer subkutanen Injektionslösung von 100 mg Anakinra in Kombination mit Riluzol bei Patienten mit Amyotropher Lateralsklerose (ALS).,2010-12-22,NA,US NCT number,results
2010-019218-26,Offene Verträglichkeitsstudie zur Evaluierung einer subkutanen Injektionslösung von 100 mg Anakinra in Kombination mit Riluzol bei Patienten mit Amyotropher Lateralsklerose (ALS).,2010-12-22,NA,ISRCTN number,results
2010-018291-25,"INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY IN MEN WITH ANDROGENETIC ALOPECIA IN THE TEMPLE AND VERTEX REGION CONCERNING HAIR VOLUME OVER 24 / 104 WEEKS",2010-06-24,NCT01319370,US NCT number,protocol
2010-018291-25,"INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY IN MEN WITH ANDROGENETIC ALOPECIA IN THE TEMPLE AND VERTEX REGION CONCERNING HAIR VOLUME OVER 24 / 104 WEEKS",2010-06-24,NA,other,protocol
2010-018291-25,"INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY IN MEN WITH ANDROGENETIC ALOPECIA IN THE TEMPLE AND VERTEX REGION CONCERNING HAIR VOLUME OVER 24 / 104 WEEKS",2010-06-24,NA,US NCT number,results
2010-018291-25,"INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY IN MEN WITH ANDROGENETIC ALOPECIA IN THE TEMPLE AND VERTEX REGION CONCERNING HAIR VOLUME OVER 24 / 104 WEEKS",2010-06-24,NA,ISRCTN number,results
2009-017739-17,Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem,2010-01-04,NA,US NCT number,protocol
2009-017739-17,Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem,2010-01-04,NA,other,protocol
2009-017739-17,Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem,2010-01-04,NA,US NCT number,results
2009-017739-17,Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem,2010-01-04,NA,ISRCTN number,results
2009-017581-22,Cognitive impairment in bipolar disorder treated with aripiprazole,2010-12-07,NA,US NCT number,protocol
2009-017581-22,Cognitive impairment in bipolar disorder treated with aripiprazole,2010-12-07,NA,other,protocol
2009-017581-22,Cognitive impairment in bipolar disorder treated with aripiprazole,2010-12-07,NA,US NCT number,results
2009-017581-22,Cognitive impairment in bipolar disorder treated with aripiprazole,2010-12-07,NA,ISRCTN number,results
2009-017458-11,"Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",2010-03-24,NA,US NCT number,protocol
2009-017458-11,"Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",2010-03-24,NA,other,protocol
2009-017458-11,"Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",2010-03-24,NA,US NCT number,results
2009-017458-11,"Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",2010-03-24,NA,ISRCTN number,results
2009-016907-41,"Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes",2012-08-13,NA,US NCT number,protocol
2009-016907-41,"Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes",2012-08-13,NA,other,protocol
2009-016907-41,"Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes",2012-08-13,NA,US NCT number,results
2009-016907-41,"Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes",2012-08-13,NA,ISRCTN number,results
2009-016482-28,SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy,2010-03-15,NA,US NCT number,protocol
2009-016482-28,SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy,2010-03-15,NA,other,protocol
2009-016482-28,SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy,2010-03-15,NA,US NCT number,results
2009-016482-28,SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy,2010-03-15,NA,ISRCTN number,results
2009-016043-19,Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base balance in patients undergoing elective hip replacement surgery,2010-02-09,NA,US NCT number,protocol
2009-016043-19,Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base balance in patients undergoing elective hip replacement surgery,2010-02-09,NA,other,protocol
2009-016043-19,Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base balance in patients undergoing elective hip replacement surgery,2010-02-09,NA,US NCT number,results
2009-016043-19,Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base balance in patients undergoing elective hip replacement surgery,2010-02-09,NA,ISRCTN number,results
2009-015319-41,Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS),2011-02-04,NA,US NCT number,protocol
2009-015319-41,Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS),2011-02-04,NA,other,protocol
2009-015319-41,Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS),2011-02-04,NA,US NCT number,results
2009-015319-41,Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS),2011-02-04,NA,ISRCTN number,results
2009-014300-55,"Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomeningeal spread",2009-12-10,NA,US NCT number,protocol
2009-014300-55,"Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomeningeal spread",2009-12-10,NA,other,protocol
2009-014300-55,"Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomeningeal spread",2009-12-10,NA,US NCT number,results
2009-014300-55,"Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomeningeal spread",2009-12-10,NA,ISRCTN number,results
2009-013976-38,Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),2009-12-07,NA,US NCT number,protocol
2009-013976-38,Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),2009-12-07,NA,other,protocol
2009-013976-38,Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),2009-12-07,NCT01693393,US NCT number,results
2009-013976-38,Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),2009-12-07,NA,ISRCTN number,results
2009-013458-33,Modulation of Cytochrome-P450 dependent eicosanoid formation by treatment with omega-3 PUFA (Omacor®),2009-09-21,NA,US NCT number,protocol
2009-013458-33,Modulation of Cytochrome-P450 dependent eicosanoid formation by treatment with omega-3 PUFA (Omacor®),2009-09-21,NA,other,protocol
2009-013458-33,Modulation of Cytochrome-P450 dependent eicosanoid formation by treatment with omega-3 PUFA (Omacor®),2009-09-21,NA,US NCT number,results
2009-013458-33,Modulation of Cytochrome-P450 dependent eicosanoid formation by treatment with omega-3 PUFA (Omacor®),2009-09-21,NA,ISRCTN number,results
2009-013432-20,"Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging",2009-06-22,NA,US NCT number,protocol
2009-013432-20,"Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging",2009-06-22,NA,other,protocol
2009-013432-20,"Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging",2009-06-22,NA,US NCT number,results
2009-013432-20,"Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging",2009-06-22,NA,ISRCTN number,results
2009-011922-33,"A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resistant recurrent ovarian cancer",2009-10-14,NA,US NCT number,protocol
2009-011922-33,"A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resistant recurrent ovarian cancer",2009-10-14,NA,other,protocol
2009-011922-33,"A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resistant recurrent ovarian cancer",2009-10-14,NCT01047891,US NCT number,results
2009-011922-33,"A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resistant recurrent ovarian cancer",2009-10-14,NA,ISRCTN number,results
2009-009656-20,Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease,2009-03-13,NA,US NCT number,protocol
2009-009656-20,Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease,2009-03-13,NA,other,protocol
2009-009656-20,Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease,2009-03-13,NA,US NCT number,results
2009-009656-20,Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease,2009-03-13,NA,ISRCTN number,results
2009-009476-12,Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy,2009-05-28,NA,US NCT number,protocol
2009-009476-12,Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy,2009-05-28,NA,other,protocol
2009-009476-12,Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy,2009-05-28,NA,US NCT number,results
2009-009476-12,Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy,2009-05-28,NA,ISRCTN number,results
2008-008474-31,Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte Studie,2009-06-26,NA,US NCT number,protocol
2008-008474-31,Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte Studie,2009-06-26,NA,other,protocol
2008-008474-31,Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte Studie,2009-06-26,NCT02094287,US NCT number,results
2008-008474-31,Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte Studie,2009-06-26,ISRCTN12345678,ISRCTN number,results
2008-008232-87,Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,2009-03-09,NA,US NCT number,protocol
2008-008232-87,Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,2009-03-09,NA,other,protocol
2008-008232-87,Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,2009-03-09,NA,US NCT number,results
2008-008232-87,Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,2009-03-09,NA,ISRCTN number,results
2008-007237-47,Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction,2008-11-19,NA,US NCT number,protocol
2008-007237-47,Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction,2008-11-19,NA,other,protocol
2008-007237-47,Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction,2008-11-19,NA,US NCT number,results
2008-007237-47,Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction,2008-11-19,NA,ISRCTN number,results
2008-007031-41,"Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",2009-09-14,NA,US NCT number,protocol
2008-007031-41,"Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",2009-09-14,NA,other,protocol
2008-007031-41,"Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",2009-09-14,NA,US NCT number,results
2008-007031-41,"Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",2009-09-14,NA,ISRCTN number,results
2008-006135-12,Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection.,2008-11-11,NA,US NCT number,protocol
2008-006135-12,Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection.,2008-11-11,NA,other,protocol
2008-006135-12,Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection.,2008-11-11,NA,US NCT number,results
2008-006135-12,Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection.,2008-11-11,NA,ISRCTN number,results
2008-005786-60,"A prospective, multicentre trial on the value of 18F-FET PET in the post-therapeutic evaluation of childhood brain tumours",2014-01-14,NA,US NCT number,protocol
2008-005786-60,"A prospective, multicentre trial on the value of 18F-FET PET in the post-therapeutic evaluation of childhood brain tumours",2014-01-14,NA,other,protocol
2008-005786-60,"A prospective, multicentre trial on the value of 18F-FET PET in the post-therapeutic evaluation of childhood brain tumours",2014-01-14,NA,US NCT number,results
2008-005786-60,"A prospective, multicentre trial on the value of 18F-FET PET in the post-therapeutic evaluation of childhood brain tumours",2014-01-14,NA,ISRCTN number,results
2008-005746-22,"Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)",2009-01-26,NA,US NCT number,protocol
2008-005746-22,"Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)",2009-01-26,NA,other,protocol
2008-005746-22,"Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)",2009-01-26,NA,US NCT number,results
2008-005746-22,"Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)",2009-01-26,NA,ISRCTN number,results
2008-005451-23,"Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin",2009-01-26,NA,US NCT number,protocol
2008-005451-23,"Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin",2009-01-26,NA,other,protocol
2008-005451-23,"Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin",2009-01-26,NA,US NCT number,results
2008-005451-23,"Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin",2009-01-26,NA,ISRCTN number,results
2008-005213-22,SUPREMES - Sunphenon in progressive forms of multiple sclerosis,2008-08-22,NA,US NCT number,protocol
2008-005213-22,SUPREMES - Sunphenon in progressive forms of multiple sclerosis,2008-08-22,NA,other,protocol
2008-005213-22,SUPREMES - Sunphenon in progressive forms of multiple sclerosis,2008-08-22,NCT00799890,US NCT number,results
2008-005213-22,SUPREMES - Sunphenon in progressive forms of multiple sclerosis,2008-08-22,NA,ISRCTN number,results
2008-005167-33,Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease,2010-03-16,NA,US NCT number,protocol
2008-005167-33,Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease,2010-03-16,NA,other,protocol
2008-005167-33,Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease,2010-03-16,NA,US NCT number,results
2008-005167-33,Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease,2010-03-16,NA,ISRCTN number,results
2008-004182-26,"Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression",2009-02-02,NA,US NCT number,protocol
2008-004182-26,"Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression",2009-02-02,NA,other,protocol
2008-004182-26,"Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression",2009-02-02,NA,US NCT number,results
2008-004182-26,"Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression",2009-02-02,NA,ISRCTN number,results
2008-003256-29,Effect of Methylnaltrexone on Postoperative Analgesic Demands,2009-01-20,NA,US NCT number,protocol
2008-003256-29,Effect of Methylnaltrexone on Postoperative Analgesic Demands,2009-01-20,NA,other,protocol
2008-003256-29,Effect of Methylnaltrexone on Postoperative Analgesic Demands,2009-01-20,NA,US NCT number,results
2008-003256-29,Effect of Methylnaltrexone on Postoperative Analgesic Demands,2009-01-20,NA,ISRCTN number,results
2008-002226-11,Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients,2008-09-03,NA,US NCT number,protocol
2008-002226-11,Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients,2008-09-03,NA,other,protocol
2008-002226-11,Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients,2008-09-03,NA,US NCT number,results
2008-002226-11,Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients,2008-09-03,NA,ISRCTN number,results
2008-001849-26,"Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus.",2008-07-29,NA,US NCT number,protocol
2008-001849-26,"Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus.",2008-07-29,NA,other,protocol
2008-001849-26,"Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus.",2008-07-29,NA,US NCT number,results
2008-001849-26,"Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus.",2008-07-29,NA,ISRCTN number,results
2008-001770-33,"INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME",2008-04-22,NA,US NCT number,protocol
2008-001770-33,"INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME",2008-04-22,NA,other,protocol
2008-001770-33,"INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME",2008-04-22,NA,US NCT number,results
2008-001770-33,"INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME",2008-04-22,NA,ISRCTN number,results
2008-000653-36,Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.,2008-05-27,NA,US NCT number,protocol
2008-000653-36,Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.,2008-05-27,NA,other,protocol
2008-000653-36,Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.,2008-05-27,NA,US NCT number,results
2008-000653-36,Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.,2008-05-27,NA,ISRCTN number,results
2008-000247-34,Prospektive randomisierte Phase II/III-Studie zur selektiven COX-2-Inhibition beim chronischen Subduralhämatom (Prospective randomized phase II/III study for the selective COX-2-inhibition in chronic subdural haematoma),2008-08-05,NA,US NCT number,protocol
2008-000247-34,Prospektive randomisierte Phase II/III-Studie zur selektiven COX-2-Inhibition beim chronischen Subduralhämatom (Prospective randomized phase II/III study for the selective COX-2-inhibition in chronic subdural haematoma),2008-08-05,NA,other,protocol
2008-000247-34,Prospektive randomisierte Phase II/III-Studie zur selektiven COX-2-Inhibition beim chronischen Subduralhämatom (Prospective randomized phase II/III study for the selective COX-2-inhibition in chronic subdural haematoma),2008-08-05,NA,US NCT number,results
2008-000247-34,Prospektive randomisierte Phase II/III-Studie zur selektiven COX-2-Inhibition beim chronischen Subduralhämatom (Prospective randomized phase II/III study for the selective COX-2-inhibition in chronic subdural haematoma),2008-08-05,NA,ISRCTN number,results
2007-007657-31,Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria,2008-02-26,NA,US NCT number,protocol
2007-007657-31,Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria,2008-02-26,NA,other,protocol
2007-007657-31,Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria,2008-02-26,NA,US NCT number,results
2007-007657-31,Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria,2008-02-26,NA,ISRCTN number,results
2007-007637-39,Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2,2008-04-15,NA,US NCT number,protocol
2007-007637-39,Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2,2008-04-15,NA,other,protocol
2007-007637-39,Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2,2008-04-15,NA,US NCT number,results
2007-007637-39,Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2,2008-04-15,NA,ISRCTN number,results
2007-007011-85,Topical application of morphine for wound healing and analgesia in patients with painful oral lesions,2010-01-29,NA,US NCT number,protocol
2007-007011-85,Topical application of morphine for wound healing and analgesia in patients with painful oral lesions,2010-01-29,NA,other,protocol
2007-007011-85,Topical application of morphine for wound healing and analgesia in patients with painful oral lesions,2010-01-29,NA,US NCT number,results
2007-007011-85,Topical application of morphine for wound healing and analgesia in patients with painful oral lesions,2010-01-29,NA,ISRCTN number,results
2007-006438-33,Influence of I(f) blockade on orthostatic tolerance and sympathic activity in healthy subjects.,2008-04-22,NA,US NCT number,protocol
2007-006438-33,Influence of I(f) blockade on orthostatic tolerance and sympathic activity in healthy subjects.,2008-04-22,NA,other,protocol
2007-006438-33,Influence of I(f) blockade on orthostatic tolerance and sympathic activity in healthy subjects.,2008-04-22,NA,US NCT number,results
2007-006438-33,Influence of I(f) blockade on orthostatic tolerance and sympathic activity in healthy subjects.,2008-04-22,NA,ISRCTN number,results
2007-006126-10,pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma,2008-07-22,NA,US NCT number,protocol
2007-006126-10,pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma,2008-07-22,NA,other,protocol
2007-006126-10,pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma,2008-07-22,NA,US NCT number,results
2007-006126-10,pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma,2008-07-22,NA,ISRCTN number,results
2007-005475-34,Prospektive Studie zur potentiellen Protektion der Ovarfunktion von Frauen mit gynäkologischen Malignomen unter Chemotherapie mittels GnRH-Analoga-Applikation,2008-03-03,NA,US NCT number,protocol
2007-005475-34,Prospektive Studie zur potentiellen Protektion der Ovarfunktion von Frauen mit gynäkologischen Malignomen unter Chemotherapie mittels GnRH-Analoga-Applikation,2008-03-03,NA,other,protocol
2007-005475-34,Prospektive Studie zur potentiellen Protektion der Ovarfunktion von Frauen mit gynäkologischen Malignomen unter Chemotherapie mittels GnRH-Analoga-Applikation,2008-03-03,NA,US NCT number,results
2007-005475-34,Prospektive Studie zur potentiellen Protektion der Ovarfunktion von Frauen mit gynäkologischen Malignomen unter Chemotherapie mittels GnRH-Analoga-Applikation,2008-03-03,NA,ISRCTN number,results
2007-004674-49,Levosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen,2007-10-30,NA,US NCT number,protocol
2007-004674-49,Levosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen,2007-10-30,NA,other,protocol
2007-004674-49,Levosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen,2007-10-30,NA,US NCT number,results
2007-004674-49,Levosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen,2007-10-30,NA,ISRCTN number,results
2007-004401-10,"Hydrocortisone for Prevention of Septic Shock Placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of low dose hydrocortisone to prevent the development of septic shock in patients with severe sepsis",2008-02-28,NA,US NCT number,protocol
2007-004401-10,"Hydrocortisone for Prevention of Septic Shock Placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of low dose hydrocortisone to prevent the development of septic shock in patients with severe sepsis",2008-02-28,clinical trials NCT 00670254,other,protocol
2007-004401-10,"Hydrocortisone for Prevention of Septic Shock Placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of low dose hydrocortisone to prevent the development of septic shock in patients with severe sepsis",2008-02-28,NCT00670254,US NCT number,results
2007-004401-10,"Hydrocortisone for Prevention of Septic Shock Placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of low dose hydrocortisone to prevent the development of septic shock in patients with severe sepsis",2008-02-28,NA,ISRCTN number,results
2007-004150-85,Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors,2007-12-04,NA,US NCT number,protocol
2007-004150-85,Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors,2007-12-04,NA,other,protocol
2007-004150-85,Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors,2007-12-04,NA,US NCT number,results
2007-004150-85,Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors,2007-12-04,NA,ISRCTN number,results
2007-004134-16,Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom,2009-02-16,NA,US NCT number,protocol
2007-004134-16,Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom,2009-02-16,NA,other,protocol
2007-004134-16,Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom,2009-02-16,NA,US NCT number,results
2007-004134-16,Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom,2009-02-16,NA,ISRCTN number,results
2007-003813-15,"CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib versus Gemcitabin über 24 Wochen – eine prospektive, randomisierte, Phase III Studie",2007-10-26,NA,US NCT number,protocol
2007-003813-15,"CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib versus Gemcitabin über 24 Wochen – eine prospektive, randomisierte, Phase III Studie",2007-10-26,NA,other,protocol
2007-003813-15,"CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib versus Gemcitabin über 24 Wochen – eine prospektive, randomisierte, Phase III Studie",2007-10-26,NA,US NCT number,results
2007-003813-15,"CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib versus Gemcitabin über 24 Wochen – eine prospektive, randomisierte, Phase III Studie",2007-10-26,NA,ISRCTN number,results
2007-003775-39,"Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis",2008-09-09,NA,US NCT number,protocol
2007-003775-39,"Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis",2008-09-09,NA,other,protocol
2007-003775-39,"Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis",2008-09-09,NA,US NCT number,results
2007-003775-39,"Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis",2008-09-09,NA,ISRCTN number,results
2007-003111-31,Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative infection rate.,2008-05-16,NA,US NCT number,protocol
2007-003111-31,Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative infection rate.,2008-05-16,ARTVI ARTVI,other,protocol
2007-003111-31,Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative infection rate.,2008-05-16,NA,US NCT number,results
2007-003111-31,Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative infection rate.,2008-05-16,NA,ISRCTN number,results
2007-002967-28,Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis,2007-08-24,NA,US NCT number,protocol
2007-002967-28,Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis,2007-08-24,NA,other,protocol
2007-002967-28,Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis,2007-08-24,NA,US NCT number,results
2007-002967-28,Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis,2007-08-24,NA,ISRCTN number,results
2007-002223-32,"A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",2008-02-07,NA,US NCT number,protocol
2007-002223-32,"A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",2008-02-07,NA,other,protocol
2007-002223-32,"A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",2008-02-07,NA,US NCT number,results
2007-002223-32,"A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",2008-02-07,NA,ISRCTN number,results
2007-002023-32,Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia,2007-06-04,NA,US NCT number,protocol
2007-002023-32,Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia,2007-06-04,NA,other,protocol
2007-002023-32,Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia,2007-06-04,NA,US NCT number,results
2007-002023-32,Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia,2007-06-04,NA,ISRCTN number,results
2007-001787-71,The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity,2007-12-17,NA,US NCT number,protocol
2007-001787-71,The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity,2007-12-17,NA,other,protocol
2007-001787-71,The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity,2007-12-17,NA,US NCT number,results
2007-001787-71,The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity,2007-12-17,NA,ISRCTN number,results
2007-001677-28,"Quantification of the anesthetic effect of nitrous oxide using intravenous ""closed-loop"" anesthesia",2007-07-02,NA,US NCT number,protocol
2007-001677-28,"Quantification of the anesthetic effect of nitrous oxide using intravenous ""closed-loop"" anesthesia",2007-07-02,NA,other,protocol
2007-001677-28,"Quantification of the anesthetic effect of nitrous oxide using intravenous ""closed-loop"" anesthesia",2007-07-02,NA,US NCT number,results
2007-001677-28,"Quantification of the anesthetic effect of nitrous oxide using intravenous ""closed-loop"" anesthesia",2007-07-02,NA,ISRCTN number,results
2007-000718-35,"CONKO-006 Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie",2007-10-18,NA,US NCT number,protocol
2007-000718-35,"CONKO-006 Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie",2007-10-18,NA,other,protocol
2007-000718-35,"CONKO-006 Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie",2007-10-18,NA,US NCT number,results
2007-000718-35,"CONKO-006 Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie",2007-10-18,NA,ISRCTN number,results
2007-000579-40,"Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",2007-10-02,NA,US NCT number,protocol
2007-000579-40,"Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",2007-10-02,NA,other,protocol
2007-000579-40,"Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",2007-10-02,NA,US NCT number,results
2007-000579-40,"Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",2007-10-02,NA,ISRCTN number,results
2007-000512-82,"Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design",2007-08-15,NA,US NCT number,protocol
2007-000512-82,"Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design",2007-08-15,NA,other,protocol
2007-000512-82,"Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design",2007-08-15,NA,US NCT number,results
2007-000512-82,"Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design",2007-08-15,NA,ISRCTN number,results
2006-006516-30,Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas.,2007-04-18,NA,US NCT number,protocol
2006-006516-30,Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas.,2007-04-18,NA,other,protocol
2006-006516-30,Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas.,2007-04-18,NA,US NCT number,results
2006-006516-30,Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas.,2007-04-18,NA,ISRCTN number,results
2006-006323-39,Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,2007-03-05,NA,US NCT number,protocol
2006-006323-39,Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,2007-03-05,NA,other,protocol
2006-006323-39,Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,2007-03-05,NA,US NCT number,results
2006-006323-39,Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,2007-03-05,NA,ISRCTN number,results
2006-006088-22,Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction,2011-02-14,NA,US NCT number,protocol
2006-006088-22,Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction,2011-02-14,NA,other,protocol
2006-006088-22,Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction,2011-02-14,NCT02158988,US NCT number,results
2006-006088-22,Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction,2011-02-14,NA,ISRCTN number,results
2006-005710-12,Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),2007-06-18,NA,US NCT number,protocol
2006-005710-12,Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),2007-06-18,NA,other,protocol
2006-005710-12,Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),2007-06-18,NA,US NCT number,results
2006-005710-12,Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),2007-06-18,NA,ISRCTN number,results
2006-005262-39,Flupirtin as Oral Treatment in MS,2007-03-09,NA,US NCT number,protocol
2006-005262-39,Flupirtin as Oral Treatment in MS,2007-03-09,NA,other,protocol
2006-005262-39,Flupirtin as Oral Treatment in MS,2007-03-09,NA,US NCT number,results
2006-005262-39,Flupirtin as Oral Treatment in MS,2007-03-09,NA,ISRCTN number,results
2006-004891-10,Future strategies for vocational rehabilitation schizophrenia,2006-11-22,NA,US NCT number,protocol
2006-004891-10,Future strategies for vocational rehabilitation schizophrenia,2006-11-22,NA,other,protocol
2006-004891-10,Future strategies for vocational rehabilitation schizophrenia,2006-11-22,NA,US NCT number,results
2006-004891-10,Future strategies for vocational rehabilitation schizophrenia,2006-11-22,NA,ISRCTN number,results
2006-004860-29,D-Cycloserine supported exposure in panic disorder,2006-12-07,NA,US NCT number,protocol
2006-004860-29,D-Cycloserine supported exposure in panic disorder,2006-12-07,NA,other,protocol
2006-004860-29,D-Cycloserine supported exposure in panic disorder,2006-12-07,NA,US NCT number,results
2006-004860-29,D-Cycloserine supported exposure in panic disorder,2006-12-07,NA,ISRCTN number,results
2006-004628-34,"Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder Tubenkarzinom",2006-12-15,NA,US NCT number,protocol
2006-004628-34,"Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder Tubenkarzinom",2006-12-15,NA,other,protocol
2006-004628-34,"Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder Tubenkarzinom",2006-12-15,NA,US NCT number,results
2006-004628-34,"Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder Tubenkarzinom",2006-12-15,NA,ISRCTN number,results
2006-004290-97,"A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS).",2006-10-17,NA,US NCT number,protocol
2006-004290-97,"A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS).",2006-10-17,NA,other,protocol
2006-004290-97,"A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS).",2006-10-17,NA,US NCT number,results
2006-004290-97,"A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS).",2006-10-17,NA,ISRCTN number,results
2006-004162-13,"Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease",2006-10-06,NA,US NCT number,protocol
2006-004162-13,"Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease",2006-10-06,NA,other,protocol
2006-004162-13,"Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease",2006-10-06,NA,US NCT number,results
2006-004162-13,"Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease",2006-10-06,NA,ISRCTN number,results
2006-003999-35,Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients,2006-10-10,NA,US NCT number,protocol
2006-003999-35,Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients,2006-10-10,NA,other,protocol
2006-003999-35,Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients,2006-10-10,NA,US NCT number,results
2006-003999-35,Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients,2006-10-10,NA,ISRCTN number,results
2006-003686-13,"An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in patients with chronic urticaria (CU).",2007-03-29,NA,US NCT number,protocol
2006-003686-13,"An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in patients with chronic urticaria (CU).",2007-03-29,NA,other,protocol
2006-003686-13,"An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in patients with chronic urticaria (CU).",2007-03-29,NA,US NCT number,results
2006-003686-13,"An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in patients with chronic urticaria (CU).",2007-03-29,NA,ISRCTN number,results
2006-003470-10,Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma.,2007-03-06,NA,US NCT number,protocol
2006-003470-10,Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma.,2007-03-06,NA,other,protocol
2006-003470-10,Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma.,2007-03-06,NA,US NCT number,results
2006-003470-10,Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma.,2007-03-06,NA,ISRCTN number,results
2006-003146-41,A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTREXATE OVER 24 WEEKS FOLLOWED BY METHOTREXATE MONOTHERAPY UP TO WEEK 48 VS. METHOTREXATE MONOTHERAPY,2006-11-23,NA,US NCT number,protocol
2006-003146-41,A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTREXATE OVER 24 WEEKS FOLLOWED BY METHOTREXATE MONOTHERAPY UP TO WEEK 48 VS. METHOTREXATE MONOTHERAPY,2006-11-23,NA,other,protocol
2006-003146-41,A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTREXATE OVER 24 WEEKS FOLLOWED BY METHOTREXATE MONOTHERAPY UP TO WEEK 48 VS. METHOTREXATE MONOTHERAPY,2006-11-23,NA,US NCT number,results
2006-003146-41,A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTREXATE OVER 24 WEEKS FOLLOWED BY METHOTREXATE MONOTHERAPY UP TO WEEK 48 VS. METHOTREXATE MONOTHERAPY,2006-11-23,NA,ISRCTN number,results
2006-002306-64,Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab,2006-10-04,NA,US NCT number,protocol
2006-002306-64,Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab,2006-10-04,NA,other,protocol
2006-002306-64,Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab,2006-10-04,NA,US NCT number,results
2006-002306-64,Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab,2006-10-04,NA,ISRCTN number,results
2006-001528-38,Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive,2006-10-17,NA,US NCT number,protocol
2006-001528-38,Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive,2006-10-17,NA,other,protocol
2006-001528-38,Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive,2006-10-17,NA,US NCT number,results
2006-001528-38,Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive,2006-10-17,NA,ISRCTN number,results
2006-000815-24,A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficient patients with actinic keratoses – a single center study,2006-05-16,NA,US NCT number,protocol
2006-000815-24,A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficient patients with actinic keratoses – a single center study,2006-05-16,NA,other,protocol
2006-000815-24,A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficient patients with actinic keratoses – a single center study,2006-05-16,NA,US NCT number,results
2006-000815-24,A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficient patients with actinic keratoses – a single center study,2006-05-16,NA,ISRCTN number,results
2005-006133-32,"An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced urticaria lesions",2006-06-28,NA,US NCT number,protocol
2005-006133-32,"An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced urticaria lesions",2006-06-28,NA,other,protocol
2005-006133-32,"An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced urticaria lesions",2006-06-28,NA,US NCT number,results
2005-006133-32,"An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced urticaria lesions",2006-06-28,NA,ISRCTN number,results
2005-005021-60,"Monozentrische, randomisierte, einfach verblindete, Placebo kontrollierte Studie im Cross over Design zur Untersuchung der Wirkung von Telmisartan (Kinzalmono 80 mg) auf Blutdruck und Endothelfunktion bei Patienten unter Hämodialysebehandlung.",2006-12-05,NA,US NCT number,protocol
2005-005021-60,"Monozentrische, randomisierte, einfach verblindete, Placebo kontrollierte Studie im Cross over Design zur Untersuchung der Wirkung von Telmisartan (Kinzalmono 80 mg) auf Blutdruck und Endothelfunktion bei Patienten unter Hämodialysebehandlung.",2006-12-05,NA,other,protocol
2005-005021-60,"Monozentrische, randomisierte, einfach verblindete, Placebo kontrollierte Studie im Cross over Design zur Untersuchung der Wirkung von Telmisartan (Kinzalmono 80 mg) auf Blutdruck und Endothelfunktion bei Patienten unter Hämodialysebehandlung.",2006-12-05,NA,US NCT number,results
2005-005021-60,"Monozentrische, randomisierte, einfach verblindete, Placebo kontrollierte Studie im Cross over Design zur Untersuchung der Wirkung von Telmisartan (Kinzalmono 80 mg) auf Blutdruck und Endothelfunktion bei Patienten unter Hämodialysebehandlung.",2006-12-05,NA,ISRCTN number,results
2005-005017-38,Efficacy of cetuximab in combination with docetaxel for the treatment of relapsed head and neck carcinoma: A clinical phase II trial,2006-06-21,NA,US NCT number,protocol
2005-005017-38,Efficacy of cetuximab in combination with docetaxel for the treatment of relapsed head and neck carcinoma: A clinical phase II trial,2006-06-21,NA,other,protocol
2005-005017-38,Efficacy of cetuximab in combination with docetaxel for the treatment of relapsed head and neck carcinoma: A clinical phase II trial,2006-06-21,NA,US NCT number,results
2005-005017-38,Efficacy of cetuximab in combination with docetaxel for the treatment of relapsed head and neck carcinoma: A clinical phase II trial,2006-06-21,NA,ISRCTN number,results
2005-003714-15,Mechanismen der Glukagon-induzierten Stimulation des Wachstumshormons; die Rolle des Glukagons in der Ghrelin-Regulation,2005-09-28,NA,US NCT number,protocol
2005-003714-15,Mechanismen der Glukagon-induzierten Stimulation des Wachstumshormons; die Rolle des Glukagons in der Ghrelin-Regulation,2005-09-28,NA,other,protocol
2005-003714-15,Mechanismen der Glukagon-induzierten Stimulation des Wachstumshormons; die Rolle des Glukagons in der Ghrelin-Regulation,2005-09-28,NA,US NCT number,results
2005-003714-15,Mechanismen der Glukagon-induzierten Stimulation des Wachstumshormons; die Rolle des Glukagons in der Ghrelin-Regulation,2005-09-28,NA,ISRCTN number,results
2005-003648-70,"Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.",2007-02-20,NA,US NCT number,protocol
2005-003648-70,"Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.",2007-02-20,NA,other,protocol
2005-003648-70,"Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.",2007-02-20,NA,US NCT number,results
2005-003648-70,"Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.",2007-02-20,NA,ISRCTN number,results
2005-003617-33,A Randomised Cross-Over Study to Explore the Pathophysiological Mechanisms Involved in the Treatment of Actinic Keratoses with Solaraze,2006-05-22,NA,US NCT number,protocol
2005-003617-33,A Randomised Cross-Over Study to Explore the Pathophysiological Mechanisms Involved in the Treatment of Actinic Keratoses with Solaraze,2006-05-22,NA,other,protocol
2005-003617-33,A Randomised Cross-Over Study to Explore the Pathophysiological Mechanisms Involved in the Treatment of Actinic Keratoses with Solaraze,2006-05-22,NA,US NCT number,results
2005-003617-33,A Randomised Cross-Over Study to Explore the Pathophysiological Mechanisms Involved in the Treatment of Actinic Keratoses with Solaraze,2006-05-22,NA,ISRCTN number,results
2005-003488-22,Regulation des Antidiuretisches Hormons (ADH) und der antidiuretischen Wirkung unter Glucocorticoid - Therapie,2006-05-22,NA,US NCT number,protocol
2005-003488-22,Regulation des Antidiuretisches Hormons (ADH) und der antidiuretischen Wirkung unter Glucocorticoid - Therapie,2006-05-22,NA,other,protocol
2005-003488-22,Regulation des Antidiuretisches Hormons (ADH) und der antidiuretischen Wirkung unter Glucocorticoid - Therapie,2006-05-22,NA,US NCT number,results
2005-003488-22,Regulation des Antidiuretisches Hormons (ADH) und der antidiuretischen Wirkung unter Glucocorticoid - Therapie,2006-05-22,NA,ISRCTN number,results
2005-003195-38,Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate 150 mg on structural properties of bone in postmenopausal osteoporosis without vertebral fractures,2005-09-12,NA,US NCT number,protocol
2005-003195-38,Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate 150 mg on structural properties of bone in postmenopausal osteoporosis without vertebral fractures,2005-09-12,NA,other,protocol
2005-003195-38,Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate 150 mg on structural properties of bone in postmenopausal osteoporosis without vertebral fractures,2005-09-12,NA,US NCT number,results
2005-003195-38,Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate 150 mg on structural properties of bone in postmenopausal osteoporosis without vertebral fractures,2005-09-12,NA,ISRCTN number,results
2005-002582-37,"Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients",2005-10-28,NA,US NCT number,protocol
2005-002582-37,"Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients",2005-10-28,NA,other,protocol
2005-002582-37,"Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients",2005-10-28,NA,US NCT number,results
2005-002582-37,"Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients",2005-10-28,NA,ISRCTN number,results
2005-002475-32,"Pilotstudy about endocrinilogical, peripherphysilogical and painreducing effects of Gamma-hydroxybutyrate in combination with operant-behaviour-therapeutic paintherapy with patients in Fibromyalgia-Syndrome",2006-05-16,NA,US NCT number,protocol
2005-002475-32,"Pilotstudy about endocrinilogical, peripherphysilogical and painreducing effects of Gamma-hydroxybutyrate in combination with operant-behaviour-therapeutic paintherapy with patients in Fibromyalgia-Syndrome",2006-05-16,NA,other,protocol
2005-002475-32,"Pilotstudy about endocrinilogical, peripherphysilogical and painreducing effects of Gamma-hydroxybutyrate in combination with operant-behaviour-therapeutic paintherapy with patients in Fibromyalgia-Syndrome",2006-05-16,NA,US NCT number,results
2005-002475-32,"Pilotstudy about endocrinilogical, peripherphysilogical and painreducing effects of Gamma-hydroxybutyrate in combination with operant-behaviour-therapeutic paintherapy with patients in Fibromyalgia-Syndrome",2006-05-16,NA,ISRCTN number,results
2005-002320-34,Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER),2006-05-16,NA,US NCT number,protocol
2005-002320-34,Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER),2006-05-16,NA,other,protocol
2005-002320-34,Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER),2006-05-16,NCT00844142,US NCT number,results
2005-002320-34,Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER),2006-05-16,NA,ISRCTN number,results
2005-001907-21,"A randomised, double-blinded, multicenter, parallel group study comparing a remifentanil-regimen with a fentanyl-regimen for analgesia in mechanically ventilated patients",2005-06-24,NA,US NCT number,protocol
2005-001907-21,"A randomised, double-blinded, multicenter, parallel group study comparing a remifentanil-regimen with a fentanyl-regimen for analgesia in mechanically ventilated patients",2005-06-24,NA,other,protocol
2005-001907-21,"A randomised, double-blinded, multicenter, parallel group study comparing a remifentanil-regimen with a fentanyl-regimen for analgesia in mechanically ventilated patients",2005-06-24,NA,US NCT number,results
2005-001907-21,"A randomised, double-blinded, multicenter, parallel group study comparing a remifentanil-regimen with a fentanyl-regimen for analgesia in mechanically ventilated patients",2005-06-24,NA,ISRCTN number,results
2005-001602-76,Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression.,2006-01-09,NA,US NCT number,protocol
2005-001602-76,Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression.,2006-01-09,NA,other,protocol
2005-001602-76,Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression.,2006-01-09,NA,US NCT number,results
2005-001602-76,Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression.,2006-01-09,NA,ISRCTN number,results
2005-001559-39,Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epithelialem Ovarialkarzinom und Peritonealkarzinom,2006-06-02,NA,US NCT number,protocol
2005-001559-39,Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epithelialem Ovarialkarzinom und Peritonealkarzinom,2006-06-02,NA,other,protocol
2005-001559-39,Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epithelialem Ovarialkarzinom und Peritonealkarzinom,2006-06-02,NA,US NCT number,results
2005-001559-39,Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epithelialem Ovarialkarzinom und Peritonealkarzinom,2006-06-02,NA,ISRCTN number,results
2005-001486-33,Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome [Sicherheit und Wirksamkeit von Levetiracetam (Keppra) für die Behandlung des stationären Alkoholentzugsyndroms],2005-06-15,NA,US NCT number,protocol
2005-001486-33,Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome [Sicherheit und Wirksamkeit von Levetiracetam (Keppra) für die Behandlung des stationären Alkoholentzugsyndroms],2005-06-15,NA,other,protocol
2005-001486-33,Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome [Sicherheit und Wirksamkeit von Levetiracetam (Keppra) für die Behandlung des stationären Alkoholentzugsyndroms],2005-06-15,NA,US NCT number,results
2005-001486-33,Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome [Sicherheit und Wirksamkeit von Levetiracetam (Keppra) für die Behandlung des stationären Alkoholentzugsyndroms],2005-06-15,NA,ISRCTN number,results
2005-001456-20,„Pilotstudie zum Einfluss selektiver neurogener Blockaden auf die perioperative Immunreaktion bei Lungen-resezierten Patienten.“,2005-11-22,NA,US NCT number,protocol
2005-001456-20,„Pilotstudie zum Einfluss selektiver neurogener Blockaden auf die perioperative Immunreaktion bei Lungen-resezierten Patienten.“,2005-11-22,NA,other,protocol
2005-001456-20,„Pilotstudie zum Einfluss selektiver neurogener Blockaden auf die perioperative Immunreaktion bei Lungen-resezierten Patienten.“,2005-11-22,NA,US NCT number,results
2005-001456-20,„Pilotstudie zum Einfluss selektiver neurogener Blockaden auf die perioperative Immunreaktion bei Lungen-resezierten Patienten.“,2005-11-22,NA,ISRCTN number,results
2004-005172-17,Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media,2006-05-22,NA,US NCT number,protocol
2004-005172-17,Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media,2006-05-22,NA,other,protocol
2004-005172-17,Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media,2006-05-22,NA,US NCT number,results
2004-005172-17,Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media,2006-05-22,NA,ISRCTN number,results
2004-004352-40,Einfluss einer präoperativen Vakzinierung auf das Immunsystem und die postoperative Infektionsrate,2004-11-30,NA,US NCT number,protocol
2004-004352-40,Einfluss einer präoperativen Vakzinierung auf das Immunsystem und die postoperative Infektionsrate,2004-11-30,NA,other,protocol
2004-004352-40,Einfluss einer präoperativen Vakzinierung auf das Immunsystem und die postoperative Infektionsrate,2004-11-30,NA,US NCT number,results
2004-004352-40,Einfluss einer präoperativen Vakzinierung auf das Immunsystem und die postoperative Infektionsrate,2004-11-30,NA,ISRCTN number,results
2004-003816-47,Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance,2005-10-19,NA,US NCT number,protocol
2004-003816-47,Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance,2005-10-19,NA,other,protocol
2004-003816-47,Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance,2005-10-19,NA,US NCT number,results
2004-003816-47,Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance,2005-10-19,NA,ISRCTN number,results
2004-000957-47,Comparison of Bisoprolol and Carvedilol in elderly patients with heart failure. A randomised doubleblind multicenter trial,2007-11-08,NA,US NCT number,protocol
2004-000957-47,Comparison of Bisoprolol and Carvedilol in elderly patients with heart failure. A randomised doubleblind multicenter trial,2007-11-08,NA,other,protocol
2004-000957-47,Comparison of Bisoprolol and Carvedilol in elderly patients with heart failure. A randomised doubleblind multicenter trial,2007-11-08,NA,US NCT number,results
2004-000957-47,Comparison of Bisoprolol and Carvedilol in elderly patients with heart failure. A randomised doubleblind multicenter trial,2007-11-08,NA,ISRCTN number,results
2021-006176-16,Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT),2022-04-04,NA,US NCT number,protocol
2021-006176-16,Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT),2022-04-04,NA,other,protocol
2021-006176-16,Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT),2022-04-04,NA,US NCT number,results
2021-006176-16,Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT),2022-04-04,NA,ISRCTN number,results
2021-006031-25,Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial),2022-04-05,NA,US NCT number,protocol
2021-006031-25,Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial),2022-04-05,NA,other,protocol
2021-006031-25,Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial),2022-04-05,NA,US NCT number,results
2021-006031-25,Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial),2022-04-05,NA,ISRCTN number,results
2021-002245-15,A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.,2021-04-30,NA,US NCT number,protocol
2021-002245-15,A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.,2021-04-30,NA,other,protocol
2021-002245-15,A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.,2021-04-30,NA,US NCT number,results
2021-002245-15,A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.,2021-04-30,NA,ISRCTN number,results
2021-001512-28,Immunogenicity of COVID-19 vaccines in medical staff and special risk populations,2021-04-13,NA,US NCT number,protocol
2021-001512-28,Immunogenicity of COVID-19 vaccines in medical staff and special risk populations,2021-04-13,NA,other,protocol
2021-001512-28,Immunogenicity of COVID-19 vaccines in medical staff and special risk populations,2021-04-13,NA,US NCT number,results
2021-001512-28,Immunogenicity of COVID-19 vaccines in medical staff and special risk populations,2021-04-13,NA,ISRCTN number,results
2021-000962-14,"A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus",2021-04-19,NA,US NCT number,protocol
2021-000962-14,"A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus",2021-04-19,NA,other,protocol
2021-000962-14,"A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus",2021-04-19,NA,US NCT number,results
2021-000962-14,"A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus",2021-04-19,NA,ISRCTN number,results
2021-000613-16,"CCR1 antagonist treatment in patients hospitalized with COVID-19 A multi-centric, randomized, double-blind, and placebo-controlled clinical phase II trial",2021-09-08,NA,US NCT number,protocol
2021-000613-16,"CCR1 antagonist treatment in patients hospitalized with COVID-19 A multi-centric, randomized, double-blind, and placebo-controlled clinical phase II trial",2021-09-08,NA,other,protocol
2021-000613-16,"CCR1 antagonist treatment in patients hospitalized with COVID-19 A multi-centric, randomized, double-blind, and placebo-controlled clinical phase II trial",2021-09-08,NA,US NCT number,results
2021-000613-16,"CCR1 antagonist treatment in patients hospitalized with COVID-19 A multi-centric, randomized, double-blind, and placebo-controlled clinical phase II trial",2021-09-08,NA,ISRCTN number,results
2021-000319-21,Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial),2021-07-01,NA,US NCT number,protocol
2021-000319-21,Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial),2021-07-01,NA,other,protocol
2021-000319-21,Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial),2021-07-01,NA,US NCT number,results
2021-000319-21,Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial),2021-07-01,NA,ISRCTN number,results
2020-006144-18,"Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418) Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ablation therapy in patients with metastatic colorectal cancer",2021-04-29,NA,US NCT number,protocol
2020-006144-18,"Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418) Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ablation therapy in patients with metastatic colorectal cancer",2021-04-29,AIO Number AIO-KRK-0419,other,protocol
2020-006144-18,"Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418) Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ablation therapy in patients with metastatic colorectal cancer",2021-04-29,NA,US NCT number,results
2020-006144-18,"Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418) Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ablation therapy in patients with metastatic colorectal cancer",2021-04-29,NA,ISRCTN number,results
2020-004399-16,"Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial",2021-02-23,NA,US NCT number,protocol
2020-004399-16,"Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial",2021-02-23,NA,other,protocol
2020-004399-16,"Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial",2021-02-23,NA,US NCT number,results
2020-004399-16,"Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial",2021-02-23,NA,ISRCTN number,results
2020-004102-63,"AN OPEN LABEL, PHASE I/II STUDY TO INVESTIGATE THE USE OF VORAXAZE™ AS INTENDED INTERVENTION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND WITH IMPAIRED RENAL FUNCTION BEING TREATED WITH HIGH-DOSE METHOTREXATE",2020-11-12,NA,US NCT number,protocol
2020-004102-63,"AN OPEN LABEL, PHASE I/II STUDY TO INVESTIGATE THE USE OF VORAXAZE™ AS INTENDED INTERVENTION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND WITH IMPAIRED RENAL FUNCTION BEING TREATED WITH HIGH-DOSE METHOTREXATE",2020-11-12,NA,other,protocol
2020-004102-63,"AN OPEN LABEL, PHASE I/II STUDY TO INVESTIGATE THE USE OF VORAXAZE™ AS INTENDED INTERVENTION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND WITH IMPAIRED RENAL FUNCTION BEING TREATED WITH HIGH-DOSE METHOTREXATE",2020-11-12,NA,US NCT number,results
2020-004102-63,"AN OPEN LABEL, PHASE I/II STUDY TO INVESTIGATE THE USE OF VORAXAZE™ AS INTENDED INTERVENTION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND WITH IMPAIRED RENAL FUNCTION BEING TREATED WITH HIGH-DOSE METHOTREXATE",2020-11-12,NA,ISRCTN number,results
2020-001493-29,Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients,2020-04-14,NA,US NCT number,protocol
2020-001493-29,Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients,2020-04-14,NA,other,protocol
2020-001493-29,Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients,2020-04-14,NA,US NCT number,results
2020-001493-29,Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients,2020-04-14,NA,ISRCTN number,results
2019-004223-20,"Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519",2021-03-30,NA,US NCT number,protocol
2019-004223-20,"Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519",2021-03-30,NA,other,protocol
2019-004223-20,"Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519",2021-03-30,NA,US NCT number,results
2019-004223-20,"Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519",2021-03-30,NA,ISRCTN number,results
2019-001235-31,Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to kallikrein-kinin pathology: Proof of concept treatment with Lanadelumab (DX-2930),2019-11-11,NA,US NCT number,protocol
2019-001235-31,Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to kallikrein-kinin pathology: Proof of concept treatment with Lanadelumab (DX-2930),2019-11-11,NA,other,protocol
2019-001235-31,Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to kallikrein-kinin pathology: Proof of concept treatment with Lanadelumab (DX-2930),2019-11-11,NA,US NCT number,results
2019-001235-31,Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to kallikrein-kinin pathology: Proof of concept treatment with Lanadelumab (DX-2930),2019-11-11,NA,ISRCTN number,results
2018-004254-22,"Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (PASTOR)",2019-06-25,NA,US NCT number,protocol
2018-004254-22,"Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (PASTOR)",2019-06-25,NA,other,protocol
2018-004254-22,"Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (PASTOR)",2019-06-25,NA,US NCT number,results
2018-004254-22,"Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (PASTOR)",2019-06-25,NA,ISRCTN number,results
2018-004136-30,"An Open-Label, Pilot Study to assess the effect of Lanadelumab on the clinical signs and symptoms of Hereditary angioedema with normal C1-inhibitor",2019-03-14,NA,US NCT number,protocol
2018-004136-30,"An Open-Label, Pilot Study to assess the effect of Lanadelumab on the clinical signs and symptoms of Hereditary angioedema with normal C1-inhibitor",2019-03-14,NA,other,protocol
2018-004136-30,"An Open-Label, Pilot Study to assess the effect of Lanadelumab on the clinical signs and symptoms of Hereditary angioedema with normal C1-inhibitor",2019-03-14,NA,US NCT number,results
2018-004136-30,"An Open-Label, Pilot Study to assess the effect of Lanadelumab on the clinical signs and symptoms of Hereditary angioedema with normal C1-inhibitor",2019-03-14,NA,ISRCTN number,results
2018-002947-27,"Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial",2019-03-07,NA,US NCT number,protocol
2018-002947-27,"Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial",2019-03-07,NA,other,protocol
2018-002947-27,"Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial",2019-03-07,NA,US NCT number,results
2018-002947-27,"Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial",2019-03-07,NA,ISRCTN number,results
2018-002938-20,Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO,2018-12-03,NA,US NCT number,protocol
2018-002938-20,Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO,2018-12-03,NA,other,protocol
2018-002938-20,Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO,2018-12-03,NA,US NCT number,results
2018-002938-20,Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO,2018-12-03,NA,ISRCTN number,results
2018-000492-32,"Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections",2018-09-19,NA,US NCT number,protocol
2018-000492-32,"Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections",2018-09-19,NA,other,protocol
2018-000492-32,"Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections",2018-09-19,NA,US NCT number,results
2018-000492-32,"Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections",2018-09-19,NA,ISRCTN number,results
2017-005151-83,INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE,2018-07-09,NA,US NCT number,protocol
2017-005151-83,INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE,2018-07-09,NA,other,protocol
2017-005151-83,INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE,2018-07-09,NA,US NCT number,results
2017-005151-83,INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE,2018-07-09,NA,ISRCTN number,results
2017-004149-26,Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction,2018-03-21,NA,US NCT number,protocol
2017-004149-26,Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction,2018-03-21,NA,other,protocol
2017-004149-26,Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction,2018-03-21,NA,US NCT number,results
2017-004149-26,Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction,2018-03-21,NA,ISRCTN number,results
2017-003813-24,"A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture",2018-05-02,NA,US NCT number,protocol
2017-003813-24,"A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture",2018-05-02,NA,other,protocol
2017-003813-24,"A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture",2018-05-02,NA,US NCT number,results
2017-003813-24,"A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture",2018-05-02,NA,ISRCTN number,results
2017-002124-24,Oral Propranolol for prevention of threshold retinopathy of prematurity,2017-09-25,NCT03083431,US NCT number,protocol
2017-002124-24,Oral Propranolol for prevention of threshold retinopathy of prematurity,2017-09-25,other Study ID No 01GM1703,other,protocol
2017-002124-24,Oral Propranolol for prevention of threshold retinopathy of prematurity,2017-09-25,NA,US NCT number,results
2017-002124-24,Oral Propranolol for prevention of threshold retinopathy of prematurity,2017-09-25,NA,ISRCTN number,results
2017-001262-25,"A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with cholinergic urticaria despite H1-antihistamine treatment.",2018-08-06,NA,US NCT number,protocol
2017-001262-25,"A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with cholinergic urticaria despite H1-antihistamine treatment.",2018-08-06,NA,other,protocol
2017-001262-25,"A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with cholinergic urticaria despite H1-antihistamine treatment.",2018-08-06,NA,US NCT number,results
2017-001262-25,"A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with cholinergic urticaria despite H1-antihistamine treatment.",2018-08-06,NA,ISRCTN number,results
2017-000697-11,"SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction",2017-12-08,NA,US NCT number,protocol
2017-000697-11,"SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction",2017-12-08,NA,other,protocol
2017-000697-11,"SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction",2017-12-08,NA,US NCT number,results
2017-000697-11,"SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction",2017-12-08,NA,ISRCTN number,results
2017-000058-21,Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial,2017-08-28,NCT03463317,US NCT number,protocol
2017-000058-21,Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial,2017-08-28,NA,other,protocol
2017-000058-21,Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial,2017-08-28,NA,US NCT number,results
2017-000058-21,Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial,2017-08-28,NA,ISRCTN number,results
2016-003802-14,Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients,2016-10-14,NA,US NCT number,protocol
2016-003802-14,Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients,2016-10-14,NA,other,protocol
2016-003802-14,Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients,2016-10-14,NA,US NCT number,results
2016-003802-14,Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients,2016-10-14,NA,ISRCTN number,results
2016-003175-22,Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP-- DuTRe-raD,2017-11-13,NA,US NCT number,protocol
2016-003175-22,Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP-- DuTRe-raD,2017-11-13,NA,other,protocol
2016-003175-22,Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP-- DuTRe-raD,2017-11-13,NA,US NCT number,results
2016-003175-22,Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP-- DuTRe-raD,2017-11-13,NA,ISRCTN number,results
2015-005757-12,"Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency with and without anaemia",2017-05-02,NA,US NCT number,protocol
2015-005757-12,"Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency with and without anaemia",2017-05-02,NA,other,protocol
2015-005757-12,"Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency with and without anaemia",2017-05-02,NA,US NCT number,results
2015-005757-12,"Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency with and without anaemia",2017-05-02,NA,ISRCTN number,results
2015-004172-30,"Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity",2021-04-16,NA,US NCT number,protocol
2015-004172-30,"Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity",2021-04-16,NA,other,protocol
2015-004172-30,"Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity",2021-04-16,NA,US NCT number,results
2015-004172-30,"Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity",2021-04-16,NA,ISRCTN number,results
2015-003429-32,"“Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”",2016-08-19,NA,US NCT number,protocol
2015-003429-32,"“Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”",2016-08-19,NA,other,protocol
2015-003429-32,"“Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”",2016-08-19,NA,US NCT number,results
2015-003429-32,"“Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”",2016-08-19,NA,ISRCTN number,results
2014-003457-34,"Safety of autologous CardAP-cells in patients with dilatative cardiomyopathy: an open, monocentric, double-arm, 3+3 dose escalation, phase I/II study",2018-07-27,NA,US NCT number,protocol
2014-003457-34,"Safety of autologous CardAP-cells in patients with dilatative cardiomyopathy: an open, monocentric, double-arm, 3+3 dose escalation, phase I/II study",2018-07-27,NA,other,protocol
2014-003457-34,"Safety of autologous CardAP-cells in patients with dilatative cardiomyopathy: an open, monocentric, double-arm, 3+3 dose escalation, phase I/II study",2018-07-27,NA,US NCT number,results
2014-003457-34,"Safety of autologous CardAP-cells in patients with dilatative cardiomyopathy: an open, monocentric, double-arm, 3+3 dose escalation, phase I/II study",2018-07-27,NA,ISRCTN number,results
2014-002439-32,A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from Uveal Melanoma,2015-02-13,NA,US NCT number,protocol
2014-002439-32,A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from Uveal Melanoma,2015-02-13,NA,other,protocol
2014-002439-32,A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from Uveal Melanoma,2015-02-13,NA,US NCT number,results
2014-002439-32,A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from Uveal Melanoma,2015-02-13,NA,ISRCTN number,results
2014-000097-19,"Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjector application (Fastjekt® Junior) in infants with acute anaphylactic reaction during a food provocation",2016-01-12,NA,US NCT number,protocol
2014-000097-19,"Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjector application (Fastjekt® Junior) in infants with acute anaphylactic reaction during a food provocation",2016-01-12,NA,other,protocol
2014-000097-19,"Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjector application (Fastjekt® Junior) in infants with acute anaphylactic reaction during a food provocation",2016-01-12,NA,US NCT number,results
2014-000097-19,"Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjector application (Fastjekt® Junior) in infants with acute anaphylactic reaction during a food provocation",2016-01-12,NA,ISRCTN number,results
2013-001599-40,"Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN).",2013-11-14,NA,US NCT number,protocol
2013-001599-40,"Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN).",2013-11-14,DRKS DRKS00004858,other,protocol
2013-001599-40,"Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN).",2013-11-14,NA,US NCT number,results
2013-001599-40,"Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN).",2013-11-14,NA,ISRCTN number,results
2013-001294-24,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Natural regulatory T-cells (nTregs) Trial.,2014-04-24,NA,US NCT number,protocol
2013-001294-24,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Natural regulatory T-cells (nTregs) Trial.,2014-04-24,NA,other,protocol
2013-001294-24,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Natural regulatory T-cells (nTregs) Trial.,2014-04-24,NCT02371434,US NCT number,results
2013-001294-24,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Natural regulatory T-cells (nTregs) Trial.,2014-04-24,NA,ISRCTN number,results
2012-001209-26,Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.,2013-09-17,NA,US NCT number,protocol
2012-001209-26,Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.,2013-09-17,NA,other,protocol
2012-001209-26,Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.,2013-09-17,NA,US NCT number,results
2012-001209-26,Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.,2013-09-17,NA,ISRCTN number,results
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,2016-02-01,NA,US NCT number,protocol
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,2016-02-01,NA,other,protocol
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,2016-02-01,NA,US NCT number,results
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,2016-02-01,NA,ISRCTN number,results
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,2012-12-17,NCT01802814,US NCT number,protocol
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,2012-12-17,NA,other,protocol
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,2012-12-17,NA,US NCT number,results
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,2012-12-17,NA,ISRCTN number,results
2011-000259-17,A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer,2011-12-07,NA,US NCT number,protocol
2011-000259-17,A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer,2011-12-07,NA,other,protocol
2011-000259-17,A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer,2011-12-07,NA,US NCT number,results
2011-000259-17,A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer,2011-12-07,NA,ISRCTN number,results
2009-014844-13,Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation.,2009-12-29,NA,US NCT number,protocol
2009-014844-13,Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation.,2009-12-29,NA,other,protocol
2009-014844-13,Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation.,2009-12-29,NA,US NCT number,results
2009-014844-13,Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation.,2009-12-29,NA,ISRCTN number,results
2009-011277-33,A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,2009-05-26,NA,US NCT number,protocol
2009-011277-33,A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,2009-05-26,NA,other,protocol
2009-011277-33,A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,2009-05-26,NCT00942747,US NCT number,results
2009-011277-33,A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,2009-05-26,NA,ISRCTN number,results
2009-009928-37,Phase 1/2 Studie: CONKO-008 Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie,2009-08-12,NA,US NCT number,protocol
2009-009928-37,Phase 1/2 Studie: CONKO-008 Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie,2009-08-12,NA,other,protocol
2009-009928-37,Phase 1/2 Studie: CONKO-008 Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie,2009-08-12,NA,US NCT number,results
2009-009928-37,Phase 1/2 Studie: CONKO-008 Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie,2009-08-12,NA,ISRCTN number,results
2008-006055-52,Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer,2008-11-17,NA,US NCT number,protocol
2008-006055-52,Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer,2008-11-17,NA,other,protocol
2008-006055-52,Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer,2008-11-17,NA,US NCT number,results
2008-006055-52,Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer,2008-11-17,NA,ISRCTN number,results
2007-003642-15,"A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects",2008-01-24,NA,US NCT number,protocol
2007-003642-15,"A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects",2008-01-24,NA,other,protocol
2007-003642-15,"A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects",2008-01-24,NA,US NCT number,results
2007-003642-15,"A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects",2008-01-24,NA,ISRCTN number,results
2007-003370-26,"A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man",2009-06-18,NA,US NCT number,protocol
2007-003370-26,"A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man",2009-06-18,NA,other,protocol
2007-003370-26,"A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man",2009-06-18,NA,US NCT number,results
2007-003370-26,"A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man",2009-06-18,NA,ISRCTN number,results
2006-006962-41,Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia,2007-08-13,NA,US NCT number,protocol
2006-006962-41,Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia,2007-08-13,NA,other,protocol
2006-006962-41,Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia,2007-08-13,NA,US NCT number,results
2006-006962-41,Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia,2007-08-13,NA,ISRCTN number,results
2006-001269-40,Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Therapy,2008-03-11,NA,US NCT number,protocol
2006-001269-40,Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Therapy,2008-03-11,NA,other,protocol
2006-001269-40,Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Therapy,2008-03-11,NA,US NCT number,results
2006-001269-40,Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Therapy,2008-03-11,NA,ISRCTN number,results
2004-002646-35,Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions,2006-05-08,NA,US NCT number,protocol
2004-002646-35,Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions,2006-05-08,NA,other,protocol
2004-002646-35,Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions,2006-05-08,NCT00568542,US NCT number,results
2004-002646-35,Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions,2006-05-08,NA,ISRCTN number,results
2014-002643-18,"REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",2018-05-03,NCT02453867,US NCT number,protocol
2014-002643-18,"REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",2018-05-03,Centre for Evidence in Transplantation Approval CET010,other,protocol
2014-002643-18,"REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",2018-05-03,NA,US NCT number,results
2014-002643-18,"REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",2018-05-03,NA,ISRCTN number,results
2014-001325-33,Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,2015-02-20,NA,US NCT number,protocol
2014-001325-33,Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,2015-02-20,NA,other,protocol
2014-001325-33,Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,2015-02-20,NCT02540395,US NCT number,results
2014-001325-33,Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,2015-02-20,NA,ISRCTN number,results
2013-003542-17,"A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine",2014-04-07,NA,US NCT number,protocol
2013-003542-17,"A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine",2014-04-07,NA,other,protocol
2013-003542-17,"A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine",2014-04-07,NA,US NCT number,results
2013-003542-17,"A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine",2014-04-07,NA,ISRCTN number,results
2007-007034-18,Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx und der Mundhöhle,2008-08-15,NA,US NCT number,protocol
2007-007034-18,Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx und der Mundhöhle,2008-08-15,NA,other,protocol
2007-007034-18,Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx und der Mundhöhle,2008-08-15,NA,US NCT number,results
2007-007034-18,Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx und der Mundhöhle,2008-08-15,NA,ISRCTN number,results
2006-005778-34,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,2007-01-05,NA,US NCT number,protocol
2006-005778-34,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,2007-01-05,NA,other,protocol
2006-005778-34,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,2007-01-05,NCT00772655,US NCT number,results
2006-005778-34,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,2007-01-05,NA,ISRCTN number,results
2004-002420-18,"A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.",2005-02-11,NA,US NCT number,protocol
2004-002420-18,"A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.",2005-02-11,NA,other,protocol
2004-002420-18,"A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.",2005-02-11,NA,US NCT number,results
2004-002420-18,"A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.",2005-02-11,NA,ISRCTN number,results
